keyword
MENU ▼
Read by QxMD icon Read
search

Lacosamide

keyword
https://www.readbyqxmd.com/read/29135908/evaluation-of-a-novel-immunoassay-for-lacosamide-therapeutic-drug-monitoring-comparison-with-a-liquid-chromatography-mass-spectrometry-assay
#1
Annachiara DʼUrso, Tiziano Ricotta, Ugo de Grazia
BACKGROUND: Monitoring serum levels of lacosamide, other than to establish individualized reference ranges may be helpful in several settings, including patients with liver and/or kidney failure or settings that may result in altered pharmacokinetic characteristics and to assess patients' compliance with therapy. In this study, the EurekaOne liquid chromatography-mass spectrometry (LC-MS/MS) method (in use method) and the ARK immunoassay method (new method) for lacosamide monitoring were compared...
December 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29111505/when-adverse-effects-are-seen-as-desirable-abuse-potential-of-the-newer-generation-antiepileptic-drugs
#2
REVIEW
Kelsey L Hawkins, Barry E Gidal
There has been growing recognition of the possible abuse potential of newer generation antiepileptic drugs, and several of these agents have been categorized as controlled substances in the United States. To properly schedule a new medication, the abuse potential, or the potential for a drug to be used for its nonmedical positive subjective effects, must be determined. Performing a human abuse potential study is one step in the overall abuse potential assessment. These studies analyze the abuse potential of a new drug in a very specific population of known recreational drug users...
October 27, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29097018/antiepileptic-drugs-and-liver-disease
#3
REVIEW
Jorge Vidaurre, Satya Gedela, Shannon Yarosz
Acute, symptomatic seizures or epilepsy may complicate the course of hepatic disease. Choosing the most appropriate antiepileptic drug in this setting represents a difficult challenge, as most medications are metabolized by the liver. This article focuses on the acute and chronic treatment of seizures in patients with advanced liver disease and reviews the hepatotoxic potential of specific antiepileptic drugs. Newer antiepileptic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy...
September 22, 2017: Pediatric Neurology
https://www.readbyqxmd.com/read/29083341/a-case-of-refractary-epilepsy-and-related-pain-due-to-dysmenorrhea-solved-with-loading-dose-of-lacosamide-clinical-and-neurophysiological-correlates
#4
Nicolino Marchitto, Umberto Ceratti, Serenella Dalmaso, Gianfranco Raimondi
 In most cases, the etiology of epilepsy is unknown, although some individuals may develop epilepsy as a result of certain brain injuries, following a stroke, a brain tumor or because of drugs and alcohol. Even some rare genetic mutations may be related to the onset of the condition. Seizures are the result of excessive and abnormal activity of neurons in the cerebral cortex. In this case report we show a clinical case of refractory epilepsy due to pain related to uncontrolled dysmenorrhea. The patient, 43 yrs old, had a history of epilepsy of 20 years and ovarian cancer...
October 23, 2017: Acta Bio-medica: Atenei Parmensis
https://www.readbyqxmd.com/read/29076421/seizures-and-anticonvulsants-in-brain-tumours-frequency-mechanisms-and-anti-epileptic-management
#5
Charles Vecht, Louis Royer-Perron, Caroline Houillier, Gilles Huberfeld
In cancer, epilepsy can be the manifestation of a primary brain tumour, metastatic disease, vascular or surgical complications, opportunistic infection or secondary to anti-tumour therapy. Seizures are frequently the first symptom of a brain tumour. The epilepsy is related to elevated extracellular glutamate stimulating NMDA- and AMPA-receptors and to the formation of D-2HG which resembles glutamate in IDH1 mutated gliomas. Epilepsy as presenting sign is associated with a longer survival in low- and high- grade gliomas, particularly with the IDH1 mutation...
October 27, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29073578/long-term-retention-rates-for-antiepileptic-drugs-a-review-of-long-term-extension-studies-and-comparison-with-brivaracetam
#6
REVIEW
Manuel Toledo, Rebecca Beale, Jennifer S Evans, Sara Steeves, Sami Elmoufti, Rebecca Townsend, John Whitesides, Simon Borghs
Antiepileptic drug (AED) retention rates are frequently reported in the literature and used to inform clinical decision-making, but methodological differences in the determination of retention rates make comparisons between trials difficult. Open-label extension (OLE) studies of AEDs in patients with focal epilepsy were identified from the literature. Retention calculation methods were reviewed, and published AED retention rates qualitatively compared with corresponding data for brivaracetam (BRV), a synaptic vesicle protein 2A ligand...
October 10, 2017: Epilepsy Research
https://www.readbyqxmd.com/read/29071470/the-challenge-of-pharmacotherapy-in-children-and-adolescents-with-epilepsy-adhd-comorbidity
#7
REVIEW
Alberto Verrotti, Romina Moavero, Gianvito Panzarino, Claudia Di Paolantonio, Renata Rizzo, Paolo Curatolo
Epilepsy is common in children and adolescents where its prevalence is 3.2-5.5/1000. About one-third of patients also have attention deficit hyperactivity/impulsivity disorder (ADHD). The possible relationship between epilepsy and ADHD is still unclear, and ADHD symptoms (such as inattention, hyperactivity, behavioral disturbances) are frequently considered as adverse effects of antiepileptic drugs (AEDs). The literature was searched for data on the behavioral effects of AEDs. Phenobarbital is the most frequently reported medication to induce symptoms of ADHD, followed by topiramate and valproic acid...
October 25, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29055470/commentary-on-neuromyelitis-optica-spectrum-disorder-related-tonic-spams-responsive-to-lacosamide
#8
Sergio Alejandro Rodríguez-Quiroga, Luz Abaroa, Luciana Melamud, Tomoko Arakaki, Nélida S Garretto, Andrés M Villa
No abstract text is available yet for this article.
October 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29053136/-lacosamide-vimpat-prospects-for-clinical-application
#9
I G Rudakova, P N Vlasov, L V Lipatova, K V Voronkova
This article presents the review of the most significant studies of the efficacy and tolerability of lacosamide (LCM) in treatment of patients with focal epilepsy. The review includes the results of the main studies which preceded the official approval of LCM use in mono- and polytherapy. Results on the efficacy of LCM in long-term use and treatment retention in clinical practice, most effective LCM combinations, tolerability, an influence on cognitive and mental functions, advantages in treatment of elderly patients are presented...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29031193/the-retention-of-lacosamide-in-patients-with-epilepsy-and-intellectual-disability-in-three-specialised-institutions
#10
J Brenner, H J M Majoie, S van Beek, J A Carpay
PURPOSE: We describe the effectiveness of lacosamide as adjunctive therapy in patients with epilepsy and an intellectual disability. This information is relevant, as few data exist pertaining to this population with a high prevalence of (intractable) epilepsy. METHODS: We performed a retrospective study in three specialised institutions. Inclusion criteria were (1) focal onset or symptomatic generalized (2) therapy-resistant epilepsy, (3) intellectual disability and (4) residence in a care-facility for people with intellectual disabilities (PWID)...
October 3, 2017: Seizure: the Journal of the British Epilepsy Association
https://www.readbyqxmd.com/read/29030718/lacosamide-in-patients-with-gliomas-and-uncontrolled-seizures-results-from-an-observational-study
#11
Roberta Rudà, Alessia Pellerino, Federica Franchino, Cinzia Bertolotti, Francesco Bruno, Francesca Mo, Enrica Migliore, Gianni Ciccone, Riccardo Soffietti
To report the efficacy and tolerability of lacosamide as an add-on treatment in patients with gliomas and uncontrolled seizures despite conventional antiepileptic drugs (AEDs). We conducted an observational study on 71 patients to describe patterns of response to lacosamide and the association between clinico-pathological factors and seizure control. We observed at 3, 6 and 9 months a seizure reduction ≥ 50% in 74.6, 76 and 86.2% of patients and a seizure freedom in 42.2, 43 and 50%, respectively. The median number of seizures in the 3 months before treatment was 13, and decreased to 3 between baseline and 6 months, and to 0...
October 13, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29019022/distribution-of-lacosamide-in-the-rat-brain-assessed-by-in-vitro-slice-technique
#12
Zsolt Gáll, Szende Vancea
Lacosamide is a newer anticonvulsant and is the only one that enhances the slow inactivation of voltage gated sodium channels. It is also claimed to have disease-modifying potential, but its pharmacokinetic properties have been much less discussed in the literature. In rats, lacosamide shows restricted distribution to tissues, and the brain-to-plasma partition coefficient (Kp) is only 0.553. In this study, the brain disposition of lacosamide was evaluated in rat brains, and its neuropharmacokinetic parameters (i...
October 10, 2017: Archives of Pharmacal Research
https://www.readbyqxmd.com/read/29017081/safety-of-intravenous-lacosamide-in-critically-ill-children
#13
Sarah S Welsh, Nan Lin, Alexis A Topjian, Nicholas S Abend
PURPOSE: Acute seizures are common in critically ill children. These patients would benefit from intravenous anti-seizure medications with few adverse effects. We reviewed the usage and effects of intravenous lacosamide in critically ill children with seizures or status epilepticus. METHODS: This retrospective series included consecutive patients who received at least one dose of intravenous lacosamide from April 2011 to February 2016 in the pediatric intensive care unit of a quaternary care children's hospital, including patients with new lacosamide initiation and continuation of outpatient oral lacosamide...
November 2017: Seizure: the Journal of the British Epilepsy Association
https://www.readbyqxmd.com/read/28991361/withdrawn-anticonvulsants-for-fibromyalgia
#14
REVIEW
Nurcan Üçeyler, Claudia Sommer, Brian Walitt, Winfried Häuser
BACKGROUND: Fibromyalgia (FM) is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue. People often report high disability levels and poor health-related quality of life (HRQoL). Drug therapy focuses on reducing key symptoms and disability, and improving HRQoL. Anticonvulsants (antiepileptic drugs) are drugs frequently used for the treatment of chronic pain syndromes. OBJECTIVES: To assess the benefits and harms of anticonvulsants for treating FM symptoms...
October 9, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28989538/erratum-efficacy-and-tolerability-of-lacosamide-for-secondary-epileptic-seizures-in-patients-with-brain-tumor-a-multicenter-observational-retrospective-study
#15
Juan Manuel Sepúlveda-Sánchez, Antonio Conde-Moreno, Manuel Barón, Javier Pardo, Gaspar Reynés, Antonio Belenguer
[This corrects the article DOI: 10.3892/ol.2017.5988.].
October 2017: Oncology Letters
https://www.readbyqxmd.com/read/28983801/electronic-health-data-predict-outcomes-after-aneurysmal-subarachnoid-hemorrhage
#16
Sahar F Zafar, Eva N Postma, Siddharth Biswal, Lucas Fleuren, Emily J Boyle, Sophia Bechek, Kathryn O'Connor, Apeksha Shenoy, Durga Jonnalagadda, Jennifer Kim, Mouhsin S Shafi, Aman B Patel, Eric S Rosenthal, M Brandon Westover
BACKGROUD: Using electronic health data, we sought to identify clinical and physiological parameters that in combination predict neurologic outcomes after aneurysmal subarachnoid hemorrhage (aSAH). METHODS: We conducted a single-center retrospective cohort study of patients admitted with aSAH between 2011 and 2016. A set of 473 predictor variables was evaluated. Our outcome measure was discharge Glasgow Outcome Scale (GOS). For laboratory and physiological data, we computed the minimum, maximum, median, and variance for the first three admission days...
October 5, 2017: Neurocritical Care
https://www.readbyqxmd.com/read/28948142/lacosamide-for-refractory-generalized-tonic-clonic-seizures-of-non-focal-origin-in-clinical-practice-a-clinical-and-veeg-study
#17
Belén Abarrategui, María Eugenia García-García, Rafael Toledano, Beatriz Parejo-Carbonell, Antonio Gil-Nagel, Irene García-Morales
•7 of 9 patients with GGE reduced ≥ 50% their tonic-clonic seizure frequency on LCM.•All 7 patients remained seizure free for > 1 year, and 2 of them for > 5 years.•In 2 of the 9 patients, both with Juvenile Absence Epilepsy, absences aggravated.•One aggravation consisted on a myoclonia and absence status, in a patient with no history of myoclonia.•VEEG paralleled clinical improvement but didn't change in a case of absence worsening.
2017: Epilepsy & Behavior Case Reports
https://www.readbyqxmd.com/read/28940083/efficacy-and-safety-of-antiepileptic-drugs-for-refractory-partial-onset-epilepsy-a-network-meta-analysis
#18
REVIEW
Qingting Hu, Fang Zhang, Wenhui Teng, Fangfang Hao, Jing Zhang, Mingxiao Yin, Naidong Wang
The optimal combination of antiepileptic drugs (AEDs) for the treatment of refractory partial-onset epilepsy is a perpetual point of debate. While several network meta-analyses (NMAs) have been published, conclusions remain controversial, especially since newer AEDs have been introduced. In our review, we included the newer AEDs to evaluate the comparative efficacy and safety of AEDs for the treatment of refractory partial-onset epilepsy. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials (Cochrane Library 2017, Issue 1) from their inception to February 18, 2017...
September 22, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/28934547/multifunctional-hybrid-compounds-derived-from-2-2-5-dioxopyrrolidin-1-yl-3-methoxypropanamides-with-anticonvulsant-and-antinociceptive-properties
#19
Michał Abram, Mirosław Zagaja, Szczepan Mogilski, Marta Andres-Mach, Gniewomir Latacz, Sebastian Baś, Jarogniew J Łuszczki, Katarzyna Kieć-Kononowicz, Krzysztof Kamiński
The focused set of new pyrrolidine-2,5-diones as potential broad-spectrum hybrid anticonvulsants was described. These derivatives integrate on the common structural scaffold the chemical fragments of well-known antiepileptic drugs such as ethosuximide, levetiracetam, and lacosamide. Such hybrids demonstrated effectiveness in two of the most widely used animal seizure models, namely, the maximal electroshock (MES) test and the psychomotor 6 Hz (32 mA) seizure models. Compound 33 showed the highest anticonvulsant activity in these models (ED50 MES = 79...
October 4, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28926841/beneficial-combination-of-lacosamide-with-retigabine-in-experimental-animals-an-isobolographic-analysis
#20
Jarogniew J Luszczki, Mirosław Zagaja, Barbara Miziak, Maria W Kondrat-Wrobel, Katarzyna Zaluska, Paula Wroblewska-Luczka, Piotr Adamczuk, Stanislaw J Czuczwar, Magdalena Florek-Luszczki
BACKGROUND/AIM: To isobolographically determine the types of interactions that occur between retigabine and lacosamide (LCM; two third-generation antiepileptic drugs) with respect to their anticonvulsant activity and acute adverse effects (sedation) in the maximal electroshock-induced seizures (MES) and chimney test (motor performance) in adult male Swiss mice. METHODS: Type I isobolographic analysis for nonparallel dose-response effects for the combination of retigabine with LCM (at the fixed-ratio of 1:1) in both the MES and chimney test in mice was performed...
September 20, 2017: Pharmacology
keyword
keyword
6065
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"